HERBERT TOD COHEN

Summary

Affiliation: Boston University
Country: USA

Publications

  1. pmc Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL
    Vipul C Chitalia
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Cell Biol 10:1208-16. 2008
  2. pmc Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data
    Marc E Lenburg
    Department of Genetics and Genomics, Boston University School of Medicine 715 Albany Street, E613 Boston, Massachusetts 02118, USA
    BMC Cancer 3:31. 2003
  3. ncbi request reprint Advances in the molecular basis of renal neoplasia
    H T Cohen
    Department of Medicine, Boston University Medical Center, MA 02118, USA
    Curr Opin Nephrol Hypertens 8:325-31. 1999
  4. ncbi request reprint An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association
    H T Cohen
    Renal and Hematology Oncology Sections, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA
    Biochem Biophys Res Commun 266:43-50. 1999
  5. ncbi request reprint Renal-cell carcinoma
    Herbert T Cohen
    Renal and Hematology Oncology Sections, Department of Medicine, Boston University School of Medicine, Evans Biomedical Research Center, Boston, MA 02118, USA
    N Engl J Med 353:2477-90. 2005
  6. ncbi request reprint Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent
    Mina I Zhou
    Renal and Hematology Oncology Sections, Departments of Medicine and Pathology, Boston University School of Medicine, 650 Albany Street, Boston, MA 02118, USA
    Cancer Res 64:1278-86. 2004
  7. pmc Jade-1, a candidate renal tumor suppressor that promotes apoptosis
    Mina I Zhou
    Renal and Hematology Oncology Sections, Departments of Medicine and Pathology, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 102:11035-40. 2005

Research Grants

  1. VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
    Herbert Cohen; Fiscal Year: 1999
  2. The pVHL/Jade-1/beta-catenin axis in renal cancer
    HERBERT TOD COHEN; Fiscal Year: 2010
  3. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2007
  4. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2007
  5. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2006
  6. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2006
  7. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2005
  8. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2004
  9. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2003
  10. VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
    Herbert Cohen; Fiscal Year: 2001

Collaborators

Detail Information

Publications7

  1. pmc Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL
    Vipul C Chitalia
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Cell Biol 10:1208-16. 2008
    ..The pVHL tumour suppressor and the Wnt tumorigenesis pathway are therefore directly linked through Jade-1...
  2. pmc Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data
    Marc E Lenburg
    Department of Genetics and Genomics, Boston University School of Medicine 715 Albany Street, E613 Boston, Massachusetts 02118, USA
    BMC Cancer 3:31. 2003
    ..To better understand this lack of agreement we profiled renal cell tumor gene expression using genome-wide microarrays (45,000 probe sets) and compare our analysis to previous microarray studies...
  3. ncbi request reprint Advances in the molecular basis of renal neoplasia
    H T Cohen
    Department of Medicine, Boston University Medical Center, MA 02118, USA
    Curr Opin Nephrol Hypertens 8:325-31. 1999
    ..This review will highlight these and other new molecular advances in the renal cancer field...
  4. ncbi request reprint An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association
    H T Cohen
    Renal and Hematology Oncology Sections, Boston Medical Center and Boston University School of Medicine, Boston, MA 02118, USA
    Biochem Biophys Res Commun 266:43-50. 1999
    ..VHL also directly interacts with the Sp1 zinc fingers and self-associates via the 96-122 domain, which furthermore suggest the domain may bind other metalloproteins and contribute to VHL dominant-negative effects...
  5. ncbi request reprint Renal-cell carcinoma
    Herbert T Cohen
    Renal and Hematology Oncology Sections, Department of Medicine, Boston University School of Medicine, Evans Biomedical Research Center, Boston, MA 02118, USA
    N Engl J Med 353:2477-90. 2005
  6. ncbi request reprint Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent
    Mina I Zhou
    Renal and Hematology Oncology Sections, Departments of Medicine and Pathology, Boston University School of Medicine, 650 Albany Street, Boston, MA 02118, USA
    Cancer Res 64:1278-86. 2004
    ..Dysregulation of the VHL protein stabilization pathway or of Jade-1 itself may therefore contribute to VHL renal disease and renal cancer pathogenesis...
  7. pmc Jade-1, a candidate renal tumor suppressor that promotes apoptosis
    Mina I Zhou
    Renal and Hematology Oncology Sections, Departments of Medicine and Pathology, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 102:11035-40. 2005
    ..Therefore, Jade-1 may be a renal tumor suppressor...

Research Grants15

  1. VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
    Herbert Cohen; Fiscal Year: 1999
    ..The VTTF and this VHL effector pathway may also have importance in vascular and renal development, and in other disease contexts, such as renal cystic disease and diabetic retinopathy. ..
  2. The pVHL/Jade-1/beta-catenin axis in renal cancer
    HERBERT TOD COHEN; Fiscal Year: 2010
    ..This pathway involves the von-Hippel-Lindau tumor suppressor, the oncoprotein beta-catenin and a novel tumor suppressor protein identified in our laboratory called Jade-1. ..
  3. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2007
    ..abstract_text> ..
  4. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2007
    ..VHL-dependent Jade-1 stabilization and modification 3. Jade-1 in apoptosis and cell stress, and modulation by VHL 4. Jade-1 as a transcription factor and in chromatin compaction, and modulation by VHL ..
  5. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2006
    ..The VHL-Jade-1 protein-protein interaction, and Jade-1 expression in renal cancer tissue 2. VHL-dependent Jade-1 stabilization and modification 3. Examination of the role of Jade-1 in apoptosis and modulation by VHL ..
  6. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2006
    ..abstract_text> ..
  7. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2005
    ..abstract_text> ..
  8. Jade-1 in cystic renal disease
    Herbert Cohen; Fiscal Year: 2004
    ..abstract_text> ..
  9. VHL, Jade-1 and protein stability in renal cancer
    Herbert Cohen; Fiscal Year: 2003
    ..The VHL-Jade-1 protein-protein interaction, and Jade-1 expression in renal cancer tissue 2. VHL-dependent Jade-1 stabilization and modification 3. Examination of the role of Jade-1 in apoptosis and modulation by VHL..
  10. VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
    Herbert Cohen; Fiscal Year: 2001
    ..The VTTF and this VHL effector pathway may also have importance in vascular and renal development, and in other disease contexts, such as renal cystic disease and diabetic retinopathy. ..
  11. VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
    Herbert Cohen; Fiscal Year: 2000
    ..The VTTF and this VHL effector pathway may also have importance in vascular and renal development, and in other disease contexts, such as renal cystic disease and diabetic retinopathy. ..
  12. The pVHL/Jade-1/beta-catenin axis in renal cancer
    HERBERT TOD COHEN; Fiscal Year: 2011
    ..This pathway involves the von-Hippel-Lindau tumor suppressor, the oncoprotein beta-catenin and a novel tumor suppressor protein identified in our laboratory called Jade-1. ..